Rossi: “We Are Preparing Something Really Important”

I think most readers here are wondering what is going on now in Andrea Rossi’s lab. We have been told by him that there will not be a presentation this year, but possibly in the first quarter of 2021. The only vague details he has provided is that they are working on issues of reliability. Gerard McEk brought up this subject with a question on the Journal of Nuclear Physics:

Gerard McEk
November 22, 2020 at 10:24 AM
Dear Andrea,
A few weeks ago you said you possibly have a solution to make the Ecat more reliable.
Have you made any progress in the reliability or are you still working on that?
Thanks, kind regards, Gerard

Andrea Rossi
November 22, 2020 at 11:29 AM
Gerard McEk:
The work is in progress, and day by day we are eliminating the weak points.
Warm Regards,
A.R.

I was curious about the difficulty of the work they are involved in is, so I followed up:

Frank Acland
November 22, 2020 at 3:26 PM
Dear Andrea,

Glad to hear you are making progress. How difficult are the problems you have to deal with?

Andrea Rossi
November 22, 2020 at 4:18 PM
Frank Acland:
I do not see problems we cannot resolve. We are preparing something really important. The work is hard, the important is to stay calm.
Warm Regards,
A.R.

And in response to a question from Xavier Pitz about what level the E-Cat has reached on a scale of “too easy” to “insane”, one year after announcing it, Rossi replied, “The answer is: “insane”. And extremely expensive.”

Posted in Uncategorized | Tagged

“Making Coherent Matter Wave Beams and their Capabilities” (New Bob Greenyer Video)

Making Coherent Matter Wave Beams and Their Capabilities

Here is Bob’s summary of the document.

A technology made possible by science proposed and developed from the 1950s by both cold war sides now is codified in an awarded and valid US patent. When you have seen this presentation, you will have a new perspective on the E-CAT SKL, EVOs, Hutchison Effect and more.

In the YouTube video description is a link to a previously classified 1984 document by Tom Bearden, titled “STAR WARS NOW! The Bohm-Aharonov Effect, Scalar Interferometry, and Soviet Weaponization”
https://drive.google.com/file/d/14RU7QSptJZfyZsu_q6_v0yW6n6AX3bz0/view

Bob also references a patent filed by Lockheed Martin Corp. titled “SYSTEMS AND METHODS FOR GENERATING COHERENT MATTERWAVE BEAMS, Patent No.: US9,502.202B2” https://patentimages.storage.googleapis.com/03/ce/8b/79a466f75c7f39/US9502202.pdf

Posted in Uncategorized | Tagged

Paper: “Future Interstellar Rockets may use Laser-induced Annihilation Reactions for relativistic drive” (Claimed COP of 1300)

Thanks to Curbina for posting the following comment and link in the Always On Thread

Leif Holmlid and Sindre Zeiner-Gundersen published a paper in Acta Astronautica that is about an experimental relativistic drive that has an efficiency of 1300 times the energy consumed by the laser used to estimulate the anhihilation-like behavior, and the kinetic energy produced. In other words, COP of 1300x!!!

https://www.lenr-forum.com/attachment/15055-1-s2-0-s0094576520303179-main-pdf/

Title of Paper: “Future interstellar rockets may use laser-induced annihilation reactions for
relativistic drive”

From the Abstract:

Here, a useful method for relativistic interstellar propulsion is described for the first time. This method gives exhaust at relativistic speeds and is a factor of at least one hundred better than normal fusion due to its increased energy output from the annihilation-like meson formation processes. It uses ordinary hydrogen as fuel so a return travel is possible after refuelling almost anywhere in space. The central nuclear processes have been studied in around 20 publications, which is considered to be sufficient evidence for the general properties. The nuclear processes give relativistic particles (kaons, pions and muons) by laser-induced annihilation-like processes in ultra-dense hydrogen H(0). The kinetic energy of the mesons is 1300 times larger than the energy of the laser pulse. This method is superior to the laser-sail method by several orders of magnitude and is suitable for large spaceships.

Posted in Uncategorized | Tagged

Rossi: ‘Very Advanced’ in Developing Product to Demonstrate

The big question that is on my mind, and I am sure that is on the mind of many other readers here, is when will we get the public presentation of the E-Cat SKL. Andrea Rossi had been saying earlier this year that it would be in 2020, but recently he has admitted that he is not ready for it.

I asked him this week what needs to be accomplished in order for the presentation to happen. He replied:

Andrea Rossi
November 11, 2020 at 1:21 PM
Frank Acland:
To have a reliable product: that’s all I need.
Warm Regards,
A.R.

From this response it appears that he does not yet have a reliable product, which makes one wonder, how far away is such a product. I followed up with another question:

Frank Acland
November 13, 2020 at 10:56 AM
Dear Andrea,

You stated recently that your presentation will occur once you have a reliable product.

a) How would you characterize your progress towards this goal?
b) When you make a presentation will it be of a commercial product, or an experimental prototype?

His response:

Andrea Rossi
November 13, 2020 at 2:06 PM
Frank Acland:
a) I think we are very advanced
b) I think it will be a commercial product
Warm Regards,
A.R.

It’s hard to know the exact state of things from brief comments such as these; Even though he states that they are ‘very advanced’ Andrea Rossi is known to be optimistic in his projections, so I am not building up any hopes for a presentation in the near future.

Posted in Uncategorized | Tagged

Interview: Fusion Researcher Lerner Contends There Was ‘No Big Bang’

Thanks to Gerard McEk for posting a link to an interview from the Asia Times with US physicist and founder of LPP Fusion, Eric Lerner. LPP Fusion is a company which is developing a process of nuclear fusion they call ‘Focus Fusion’ which they describe as a “Dense Plasma Focus device with aneutronic hydrogen-boron fuel”

The interview is dialogue between Eric Lerner and Jonathan Tennenbaum. This link is to the first part of four-part interview titled “The Big Bang Never Happened but Fusion Will.”

https://asiatimes.com/2020/11/the-big-bang-never-happened-but-fusion-will/

Here is a short excerpt from Lerner:

“Saying that the Big Bang theory is a well-confirmed theory is very much like saying that the emperor’s clothes are beautiful. It’s something that lots of people agree on because ultimately their jobs and income depend on it. But it’s not something that’s backed up by scientific evidence.”

“Whenever and wherever you look at what the Big Bang hypothesis predicts, and you compare with observations, then in almost every single case you get a mass of contradictions.”

COVID-19: Press Release “Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study”

The following is a press release from Pfizer and BioNTech SE.

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

  • Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
  • Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
  • Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; safety and additional efficacy data continue to be collected
  • Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
  • Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints

NEW YORK and MAINZ, GERMANY, November 9, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases.

The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continues to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech Co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from seven days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at https://www.pfizer.com/science/coronavirus.

Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.

Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced. Based on supply projections, we expect to supply globally up to 50 million vaccine doses in 2020 and manufacture up to 1.3 billion doses in 2021. Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.